God's Gift to Women: The Human Papillomavirus Vaccine

Immunity

Volumn 25, Issue 2, 2006, Pages 179-184

  Frazer, Ian ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; PAPILLOMA VIRUS VACCINE; PROTEIN E2; PROTEIN E6; PROTEIN E7; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS VACCINE; WART VIRUS VACCINE;

ANTIVIRAL ACTIVITY; ARTICLE; CANCER RISK; CELLULAR IMMUNITY; CLINICAL TRIAL; DEVELOPING COUNTRY; DRUG EFFECT; FEMALE; GYNECOLOGIC DISEASE; HEALTH CARE ACCESS; HIGH RISK POPULATION; HOMOSEXUALITY; HUMAN; IMMUNE DEFICIENCY; INFECTION RISK; PRIORITY JOURNAL; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASE; TREATMENT OUTCOME; UTERINE CERVIX CANCER; VIRUS CAPSID; VIRUS CARCINOGENESIS; VIRUS INFECTION; VIRUS PARTICLE; WART VIRUS;

EID: 33747231266     PISSN: 10747613     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.immuni.2006.08.002     Document Type: Note

References (26)

1. Buck C.B., Pastrana D.V., Lowy D.R., and Schiller J.T. Generation of HPV pseudovirions using transfection and their use in neutralization assays. Methods Mol. Med. 119 (2005) 445-462
2. Campo M.S. Vaccination against papillomavirus in cattle. Curr. Top. Microbiol. Immunol. 186 (1994) 255-266
3. Carter J.J., Koutsky L.A., Wipf G.C., Christensen N.D., Lee S.K., Kuypers J., Kiviat N., and Galloway D.A. The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J. Infect. Dis. 174 (1996) 927-936
4. Carter J.J., Wipf G.C., Madeleine M.M., Schwartz S.M., Koutsky L.A., and Galloway D.A. Identification of human papillomavirus type 16 L1 surface loops required for neutralization by human sera. J. Virol. 80 (2006) 4664-4672
5. Chen X.S., Garcea R.L., Goldberg I., Casini G., and Harrison S.C. Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Mol. Cell 5 (2000) 557-567
6. Christensen N.D., Reed C.A., Cladel N.M., Hall K., and Leiserowitz G.S. Monoclonal antibodies to HPV-6 L1 virus-like particles identify conformational and linear neutralizing epitopes on HPV-11 in addition to type-specific epitopes on HPV-6. Virology 224 (1996) 477-486
7. Ferguson M., Heath A., Johnes S., Pagliusi S., and Dillner J. Results of the first WHO international collaborative study on the standardization of the detection of antibodies to human papillomaviruses. Int. J. Cancer 118 (2006) 1508-1514
8. Frazer I.H. Prevention of cervical cancer through papillomavirus vaccination. Nat. Rev. Immunol. 4 (2004) 46-54
9. Frazer I.H., Leippe D.M., Dunn L.A., Liem A., Tindle R.W., Fernando G.J., Phelps W.C., and Lambert P.F. Immunological responses in human papillomavirus 16 E6/E7- transgenic mice to E7 protein correlate with the presence of skin disease. Cancer Res. 55 (1995) 2635-2639
10. Frazer I.H., Mackay I.R., Crapper R.M., Jones B., Gust I.D., Sarngadharan M., Campbell D.C., and Ungar B. Immunological abnormalities in asymptomatic homosexual men: correlation with antibody to HTLV-III and sequential changes over two years. Q. J. Med. 61 (1986) 921-933
11. Frazer I.H., Medley G., Crapper R.M., Brown T.C., and Mackay I.R. Association between anorectal dysplasia, human papillomavirus, and human immunodeficiency virus infection in homosexual men. Lancet 2 (1986) 657-660
12. Harper D.M., Franco E.L., Wheeler C.M., Moscicki A.B., Romanowski B., Roteli-Martin C.M., Jenkins D., Schuind A., Clemens S.A.C., and Dubin G. Sustained efficacy up to 4-5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: Follow-up from a randomised control trial. Lancet 367 (2006) 1247-1255
13. Kidd J.G., Beard J.W., and Rous P. Serological reactions with a virus causing rabbit papillomas which become cancerous. J. Exp. Med. 64 (1936) 63-77
14. Kirnbauer R., Booy F., Cheng N., Lowy D.R., and Schiller J.T. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc. Natl. Acad. Sci. USA 89 (1992) 12180-12184
15. Lowy D.R., and Schiller J.T. Prophylactic human papillomavirus vaccines. J. Clin. Invest. 116 (2006) 1167-1173
16. McFadyean J., and Hobday F. Notes on the experimental transmission of warts in the dog. J. Comp. Path. Ther. 11 (1898) 341-342
17. Ramoz N., Rueda L.A., Bouadjar B., Montoya L.S., Orth G., and Favre M. Mutations in two adjacent novel genes are associated with epidermodysplasia verruciformis. Nature Genet. 32 (2002) 579-581
18. Rose R.C., Bonnez W., Reichman R.C., and Garcea R.L. Expression of human papillomavirus type 11 L1 protein in insect cells: In vivo and in vitro assembly of viruslike particles. J. Virol. 67 (1993) 1936-1944
19. Suzich J.A., Ghim S.J., Palmer-Hill F.J., White W.I., Tamura J.K., Bell J.A., Newsome J.A., Jenson A.B., and Schlegel R. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc. Natl. Acad. Sci. USA 92 (1995) 11553-11557
20. Tindle R.W., Fernando G.J., Sterling J.C., and Frazer I.H. A "public" T-helper epitope of the E7 transforming protein of human papillomavirus 16 provides cognate help for several E7 B- cell epitopes from cervical cancer-associated human papillomavirus genotypes. Proc. Natl. Acad. Sci. USA 88 (1991) 5887-5891
21. Villa L.L., Ault K.A., Giuliano A.R., Costa R.L., Petta C.A., Andrade R.P., Brown D.R., Ferenczy A., Harper D.M., Koutsky L.A., et al. Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18. Vaccine 24 (2006) 5571-5583
22. Yuan H., Estes P.A., Chen Y., Newsome J., Olcese V.A., Garcea R.L., and Schlegel R. Immunization with a pentameric L1 fusion protein protects against papillomavirus infection. J. Virol. 75 (2001) 7848-7853
23. Zhang L.F., Zhou J., Chen S., Cai L.L., Bao Q.Y., Zheng F.Y., Lu J.Q., Padmanabha J., Hengst K., Malcolm K., and Frazer I.H. HPV6b virus like particles are potent immunogens without adjuvant in man. Vaccine 18 (2000) 1051-1105
24. Zhou J., Stenzel D.J., Sun X.Y., and Frazer I.H. Synthesis and assembly of infectious bovine papillomavirus particles in vitro. J. Gen. Virol. 74 (1993) 763-768
25. Zhou J., Sun X.Y., Stenzel D.J., and Frazer I.H. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 185 (1991) 251-257
26. Zur Hausen H. Human papillomaviruses and their possible role in squamous cell carcinomas. Curr. Top. Microbiol. Immunol. 78 (1977) 1-30